Serum opsonins and chemotactins in neutropenic oncology patients.
Serum opsonins and chemotactins, C3 and C5, were studied in neutropenic oncology patients. Our data indicate that these individuals possess normal serum chemotactins and adequate opsonin activity regardless of disease status or prior chemotherapy. Their sera should therefore support function of transfused granulocytes.
D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion; D002633:Chemotaxis; D002648:Child; D002675:Child, Preschool; D003176:Complement C3 / Q000032:analysis; D003182:Complement C5 / Q000032:analysis; D006098:Granulocytes / Q000276:immunology; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000628:therapy*; D009895:Opsonin Proteins / Q000032:analysis*; D013210:Staphylococcus / Q000276:immunology
D003176:Complement C3; D003182:Complement C5; D009895:Opsonin Proteins